Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11 Mln
P/E Ratio
--
P/B Ratio
13.53
Industry P/E
--
Debt to Equity
1.14
ROE
-7.38 %
ROCE
-1059.47 %
Div. Yield
0 %
Book Value
0.28
EPS
-2.65
CFO
$-77.42 Mln
EBITDA
$-97.36 Mln
Net Profit
$-101.86 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biocardia Inc (BCDA)
| 39.91 | 8.93 | 33.77 | -46.01 | -49.93 | -47.66 | -33.42 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Biocardia Inc (BCDA)
| -77.71 | -68.42 | 7.73 | -43.93 | -5.98 | -65.93 | -48.75 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous... mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Address: 320 Soquel Way, Sunnyvale, CA, United States, 94085 Read more
CEO, President & Director
Dr. Peter A. Altman Ph.D.
CEO, President & Director
Dr. Peter A. Altman Ph.D.
Headquarters
Sunnyvale, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biocardia Inc (BCDA) stood at $ 4 Mln as on 31-Dec-24
The share price of Biocardia Inc (BCDA) is $3.05 (NASDAQ) as of 29-Apr-2025 16:06 EDT. Biocardia Inc (BCDA) has given a return of -49.93% in the last 3 years.
Biocardia Inc (BCDA) has a market capitalisation of $ 11 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Biocardia Inc (BCDA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biocardia Inc (BCDA) and enter the required number of quantities and click on buy to purchase the shares of Biocardia Inc (BCDA).
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Address: 320 Soquel Way, Sunnyvale, CA, United States, 94085
The CEO & director of Dr. Peter A. Altman Ph.D.. is Biocardia Inc (BCDA), and CFO & Sr. VP is Dr. Peter A. Altman Ph.D..
There is no promoter pledging in Biocardia Inc (BCDA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Biocardia Inc (BCDA) | Ratios |
|---|---|
|
Return on equity(%)
|
2074.67
|
|
Operating margin(%)
|
-13794.83
|
|
Net Margin(%)
|
-13700
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biocardia Inc (BCDA) was $0 Mln.
$0.63
(
